Tag: Atrial Fibrillation
Canadian Cardiovascular Society Updates A-Fib Guidelines
Update focuses on management of antithrombotic tx, non-vitamin K antagonist oral anticoagulant tx
A-Fib Tied to Adverse Outcomes in Patients Undergoing PCI
Condition is linked to post-procedural bleeding, heart failure, cardiogenic shock, in-hospital mortality
DAPT Use Variable in Patients With A-Fib at Risk of Stroke
Dual antiplatelet therapy used in variable manner; most patients remain on study drug after PCI
Usual Apixaban Dosing OK With One Dose-Reduction Criterion
5 mg apixaban twice daily deemed safe, appropriate for those with one criterion in ARISTOTLE trial
